Page last updated: 2024-11-07

gi 90291

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

GI 90291: major metabolite of remifentanil [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID131560
CHEMBL ID1001
SCHEMBL ID1952247
MeSH IDM0223421

Synonyms (20)

Synonym
unii-e1ezx4s2e1
1-piperidinepropanoic acid, 4-(methoxycarbonyl)-4-((1-oxopropyl)phenylamino)-
4-methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine propionic acid
gr90291
gi 90291
gr-90291
e1ezx4s2e1 ,
remifentanil acid
gi-90291
132875-68-4
gr 90291
gi90291
gr 90291c
CHEMBL1001
3-[4-methoxycarbonyl-4-(n-propanoylanilino)piperidin-1-yl]propanoic acid
SCHEMBL1952247
DTXSID60157827
remifentanil hydrochloride impurity c [ep impurity]
3-(4-(methoxycarbonyl)-4-(phenyl(propanoyl)amino)piperidin-1-yl)propanoic acid
PD057618

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The terminal half-life of remifentanil ranged from 10 to 21 min."( Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery.
Hoke, JF; Hug, CC; Muir, KT; Sebel, PS; Westmoreland, CL, 1993
)
0.29
" During and after the infusion, arterial blood was obtained for pharmacokinetic analyses, and the ventilatory response to a hypercarbic challenge was assessed."( Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease.
Connors, PM; Dershwitz, M; Dienstag, JL; Hoke, JF; Michałowski, P; Muir, KT; Rosow, CE, 1996
)
0.29
"There were no differences in any of the pharmacokinetic parameters for remifentanil or GR90291 between the two groups."( Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease.
Connors, PM; Dershwitz, M; Dienstag, JL; Hoke, JF; Michałowski, P; Muir, KT; Rosow, CE, 1996
)
0.29
" Remifentanil was rapidly eliminated, with a terminal half-life of 6 min, compared with 19 min for GR90291 and alfentanil."( Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs.
Cunningham, F; Hoffman, WE; Hoke, JF; James, MK; Muir, KT, 1997
)
0.3
" The pharmacokinetics of remifentanil were fit using a one-compartment pharmacokinetic model."( Pharmacokinetics and pharmacodynamics of remifentanil in persons with renal failure compared with healthy volunteers.
Connors, PM; Dershwitz, M; Glass, PS; Hoke, JF; Malthouse-Dufore, S; Martel, D; Michałowski, P; Muir, KT; Rosow, CE; Rubin, N; Shlugman, D, 1997
)
0.3
"The purpose of this study was to investigate the in vivo pharmacodynamics and the pharmacodynamic interactions of remifentanil and its major metabolite, GR90291, in a rat electroencephalographic model."( The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model.
Cox, EH; Danhof, M; Gubbens-Stibbe, JM; Langemeijer, MW; Muir, KT, 1999
)
0.3
" Arterial blood samples were collected and analyzed by mass spectroscopy to determine remifentanil pharmacokinetic profiles."( Pharmacokinetics of remifentanil in anesthetized pediatric patients undergoing elective surgery or diagnostic procedures.
Davis, PJ; Dear Gd, GL; Ginsberg, B; Henson, LG; Huffman, C; McGowan, FX; Muir, KT; Ross, AK; Stiller, RD, 2001
)
0.31

Dosage Studied

ExcerptRelevanceReference
" This suggests that remifentanil may not need to be dosed according to body weight in adult patients."( Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery.
Hoke, JF; Hug, CC; Muir, KT; Sebel, PS; Westmoreland, CL, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID73902Inhibition of electrically evoked contraction in guinea pig ileum determined in vitro1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgetics.
AID177922Analgesic effect calculated using in vivo rat tail withdrawal assay.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgetics.
AID174621Duration of analgesic effect calculated using in vivo rat tail withdrawal assay.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgetics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's9 (90.00)18.2507
2000's1 (10.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.68 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (10.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]